Drug Resistance in Visceral Leishmaniasis

Visceral leishmaniasis remains a public health problem worldwide. This illness was included by the World Health Organization in the list of neglected tropical diseases targeted for elimination by 2015. The widespread emergence of resistance to pentavalent antimonials in India where half cases occur globally and the unavailability of a vaccine in clinical use constitute major obstacles in achieving this goal. The last decade new antileishmanials became available, including the oral agent miltefosine. However, in poor endemic countries their wide use was curtailed because of the high costs, and also due to concerns of toxicity and emergence of resistance. Various mechanisms of antileishmanial resistance were identified recently in field isolates. Their elucidation will boost the design of new drugs and the molecular surveillance of resistance. Combination regimens should be evaluated in large trials. Overall, the development of antileishmanials has been generally slow; new drugs are needed. In order to control visceral leishmaniasis worldwide, treatment advances should become affordable in the poorest countries, where they are needed most.

• Publication year

  2009

• Venue

  Journal of Biomedicine and Biotechnology

• Publication date

  2009-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2010/617521PMID 19888437PMCID 2771279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP).

  2009cited by this paper
• Leishmania commandeers the host inflammatory response through neutrophils.

  2009cited by this paper
• Miltefosine Promotes IFN-γ-Dominated Anti-Leishmanial Immune Response1

  2009cited by this paper
• Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

  2009influential reference
• Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.

  2009cited by this paper
• Paromomycin: uptake and resistance in Leishmania donovani.

  2009cited by this paper
• Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.

  2009cited by this paper
• Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates.

  2009cited by this paper
• Visceral leishmaniasis: advances in treatment.

  2008cited by this paper
• Amphotericin B formulations and drug targeting.

  2008cited by this paper
• New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

  2008cited by this paper
• Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid Movement

  2008cited by this paper
• Antileishmanial activity of nano-amphotericin B deoxycholate.

  2008cited by this paper
• Roles of Trypanothione S-Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials

  2008cited by this paper
• Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients

  2008cited by this paper
• The Relationship between Leishmaniasis and AIDS: the Second 10 Years

  2008cited by this paper
• Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII.

  2008cited by this paper
• Drug regimens for visceral leishmaniasis in Mediterranean countries

  2008cited by this paper
• Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.

  2008cited by this paper
• Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.

  2007cited by this paper
• Neutrophils Contribute to Development of a Protective Immune Response during Onset of Infection with Leishmania donovani

  2007cited by this paper
• Injectable paromomycin for Visceral leishmaniasis in India.

  2007cited by this paper
• Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8+ Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13

  2007cited by this paper
• In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum.

  2007cited by this paper
• Characterization of natural antimony resistance in Leishmania donovani isolates.

  2007cited by this paper
• Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.

  2007cited by this paper
• Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

  2007cited by this paper
• Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

  2007cited by this paper
• Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection

  2007cited by this paper
• Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.

  2007cited by this paper
• Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice.

  2007cited by this paper
• Interleukin-10 and the pathogenesis of human visceral leishmaniasis.

  2007cited by this paper
• Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.

  2007cited by this paper
• Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.

  2007influential reference
• Epidemiology and Clinical Features of Patients with Visceral Leishmaniasis Treated by an MSF Clinic in Bakool Region, Somalia, 2004–2006

  2007cited by this paper
• Drug resistance mechanisms in clinical isolates of Leishmania donovani.

  2006cited by this paper
• Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.

  2006cited by this paper
• In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs

  2006cited by this paper
• Immune responses in kala-azar.

  2006influential reference
• Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

  2006influential reference
• Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by Inhibiting Drug Efflux

  2006cited by this paper
• A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.

  2006cited by this paper
• Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.

  2006cited by this paper
• Flavonoid Dimers as Bivalent Modulators for Pentamidine and Sodium Stiboglucanate Resistance in Leishmania

  2006cited by this paper
• Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani.

  2006cited by this paper
• Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate.

  2006cited by this paper
• Resistance of Leishmania donovani to Sodium Stibogluconate Is Related to the Expression of Host and Parasite γ-Glutamylcysteine Synthetase

  2006cited by this paper
• History of kala-azar in India. 1947.

  2006cited by this paper
• The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control.

  2006cited by this paper
• Alteration of Fatty Acid and Sterol Metabolism in Miltefosine-Resistant Leishmania donovani Promastigotes and Consequences for Drug-Membrane Interactions

  2005cited by this paper
• Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania.

  2005cited by this paper
• Gene Expression Analysis of the Mechanism of Natural Sb(V) Resistance in Leishmania donovani Isolates from Nepal

  2005cited by this paper
• Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis.

  2005cited by this paper
• Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models

  2005cited by this paper
• Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

  2003cited by this paper
• Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation.

  2003cited by this paper
• Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.

  2002cited by this paper
• Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy

  2002cited by this paper
• Drug resistance in Indian visceral leishmaniasis

  2001cited by this paper
• Visceral leishmaniasis during childhood in southern Greece.

  2000cited by this paper
• Endogenous IL‐4 is necessary for effective drug therapy against visceral leishmaniasis

  2000cited by this paper
• Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

  2000cited by this paper
• Pediatric visceral leishmaniasis in southern France.

  1998cited by this paper
• Gene Amplification in Leishmania tarentolae Selected for Resistance to Sodium Stibogluconate

  1998cited by this paper
• Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

  1998cited by this paper
• Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.

  1996cited by this paper
• Ketoconazole in the treatment of visceral leishmaniasis (kala-azar)

  1996cited by this paper
• Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis.

  1995cited by this paper
• Clinicoepidemiological study of drug resistance in Indian kala - azar

  1994cited by this paper
• Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.

  1994cited by this paper
• Ketoconazole in treatment of visceral leishmaniasis.

  1990cited by this paper
• Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study

  1988cited by this paper
• Comparison of regimens of treatment with sodium stibogluconate in kala-azar.

  1984cited by this paper

• Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis

  2026cites this paper
• Structural attributes of leishmanial phosphoenolpyruvate carboxykinase and identification of its novel inhibitors

  2026cites this paper
• An insight into the role of nanotechnology in photothermal and photodynamic therapy of leishmaniasis.

  2026cites this paper
• Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment

  2025cites this paper
• Hemophagocytic lymphohistiocytosis secondary to visceral leishmaniasis in children: case report and systematic review

  2025cites this paper
• Synthesis and mechanistic insights of Coumarinyl-Indolinone hybrids as potent inhibitors of Leishmania major.

  2025cites this paper
• Exploring bioactive molecules released during inter- and intraspecific competition: A paradigm for novel antiparasitic drug discovery and design for human use

  2025cites this paper
• Leishmaniasis: A Multifaceted Approach to Diagnosis, Maladies, Drug Repurposing and Way Forward

  2025cites this paper
• Harnessing Liposomal Formulations for Effective Treatment of Leishmaniasis: Current Strategies and Future Perspectives

  2025cites this paper
• Synthesis and evaluation of nitrochromene derivatives as potential antileishmanial therapeutics through biological and computational studies

  2025cites this paper
• Molecular Mechanisms of Drug Resistance in Leishmania spp.

  2024cites this paper
• Investigational new drugs for the treatment of leishmaniasis

  2024cites this paper
• Antiparasitic activity of the iron-containing milk protein lactoferrin and its potential derivatives against human intestinal and blood parasites

  2024cites this paper
• Identification of novel inhibitors from Rubus ellipticus as anti-leishmanial agents targeting DDX3-DEAD box RNA helicase of Leishmania donovani

  2024cites this paper
• The expression of the miR-193, miR-122 and miR-155 profiling and evaluation the serum lipid in antimony-susceptible and resistance patients with cutaneous leishmaniasis

  2024cites this paper
• Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines

  2023cites this paper
• In vitro screening of natural product-based compounds for leishmanicidal activity

  2023cites this paper
• Localized Leishmania major infection causes systemic iron deficiency that can be controlled by oral iron supplementation

  2022influential citation
• Genome-wide analysis reveals allelic variation and chromosome copy number variation in paromomycin-resistant Leishmania donovani

  2022cites this paper
• New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies.

  2022cites this paper
• Synthesis of aminochalcones and in silico evaluation of their antiparasitic potential against Leishmania

  2022cites this paper
• Effect of Acyl Chain Length on Hydrophobized Cashew Gum Self-Assembling Nanoparticles: Colloidal Properties and Amphotericin B Delivery

  2022cites this paper
• Leishmania donovani Dipeptidylcarboxypeptidase Inhibitor as a Potential Oral Treatment for Visceral Leishmaniasis

  2022cites this paper
• Aminoacyl-tRNA synthetase (AARS) as an attractive drug target in Neglected Tropical Trypanosomatid Diseases-Leishmaniasis, Human African trypanosomiasis and Chagas disease.

  2022cites this paper
• Role of two aminoacyl-tRNA synthetase associated proteins (Endothelial Monocyte Activating Polypeptides 1 and 2) of Leishmania donovani in chemotaxis of human monocytes.

  2021cites this paper
• Cysteine proteases as potential targets for anti-trypanosomatid drug discovery.

  2021cites this paper
• Use of Cell Biology to Identify Cellular Targets in Drug Development Process against Leishmania Sp.

  2021cites this paper
• Drug Resistance in Protozoal Infections

  2021cites this paper
• Treatment of canine visceral leishmaniasis with Milteforan™ induces Leishmania infantum resistance to miltefosine and amphotericin B

  2021cites this paper
• Leishmania Protein Kinases: Important Regulators of the Parasite Life Cycle and Molecular Targets for Treating Leishmaniasis

  2021cites this paper
• microRNAs: Are they Important in the Development of Resistance in Leishmaniasis?

  2021cites this paper
• Perspectives From Systems Biology to Improve Knowledge of Leishmania Drug Resistance

  2021cites this paper
• Drug repurposing based novel anti-leishmanial drug screening using in-silico and in-vitro approaches

  2021cites this paper
• The study of P-glycoprotein A, G-glutamylcysteine synthetase 1, and aquaglyceroporin 1 genes expression in non-healing zoonotic cutaneous leishmaniasis cases

  2021cites this paper
• Recent advances in identification of potential drug targets and development of novel drugs in parasitic diseases. Part I: Drug resistance

  2021influential citation
• Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol

  2021cites this paper
• Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of Leishmania donovani nuclear DNA primase using ligand based virtual screening, docking and molecular dynamics approaches

  2020cites this paper
• Epidemiological and clinical characteristics of infants with visceral leishmaniasis hospitalized in Ardabil city Hospital during 2011–2016

  2020cites this paper
• Ethanolic Extract of the Fungus Trichoderma asperelloides Induces Ultrastructural Effects and Death on Leishmania amazonensis

  2020cites this paper
• Pyridoxal Kinase from Leishmania donovani in complex with ADP and Pyridoxamine

  2020cites this paper
• Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.

  2020cites this paper
• Genomic and Transcriptomic Analysis for Identification of Genes and Interlinked Pathways Mediating Artemisinin Resistance in Leishmania donovani

  2020cites this paper
• Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy

  2020cites this paper
• Carrier-Mediated Drug Uptake in Fungal Pathogens

  2020cites this paper
• A Novel Class of Azoles with potent Anti-Leishmanial activity

  2020cites this paper
• Recent evolution on synthesis strategies and anti-leishmanial activity of β-carboline derivatives – An update

  2020cites this paper
• Differentially modulated proteins associated with Leishmaniasis—a systematic review of in-vivo and in-vitro studies

  2020cites this paper
• Structural attributes and substrate specificity of pyridoxal kinase from Leishmania donovani.

  2020cites this paper
• Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis†

  2020cites this paper
• Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria

  2020cites this paper
• Evaluation of the Knowledge, Attitudes and Prevention Practices with Regard to Cutaneous Leishmaniasis Caused by Leishmania aethiopica in Mount Elgon Focus, Kenya

  2020cites this paper
• Leishmania donovani chaperonin TCP1γ subunit protects miltefosine induced oxidative damage.

  2020cites this paper
• Synthesis of novel quinoline-based thiadiazole, evaluation of their antileishmanial potential and molecular docking studies.

  2019cites this paper
• LeishInDB: A web-accessible resource for small molecule inhibitors against Leishmania sp.

  2019cites this paper
• Identification of dehydroxy isoquine and isotebuquine as promising antileishmanial agents

  2019cites this paper
• An Overview of Drug Resistance in Protozoal Diseases

  2019influential citation
• Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.

  2019cites this paper
• Validation of NAD synthase inhibitors for inhibiting the cell viability of Leishmania donovani: In silico and in vitro approach

  2019cites this paper
• Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

  2019cites this paper
• Leishmania treatment and prevention: Natural and synthesized drugs.

  2018cites this paper
• Synthesis of Novel Agents for the treatment of Infectious and Neurodegenerative diseases

  2018cites this paper
• Amino Acids in the Development of Prodrugs

  2018cites this paper
• NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis

  2018cites this paper
• Leishmanicidal activity of α-bisabolol from Tunisian chamomile essential oil

  2018cites this paper
• Genetic manipulation of Leishmania donovani threonyl tRNA synthetase facilitates its exploration as a potential therapeutic target

  2018cites this paper
• Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis

  2018cites this paper
• Antileishmanial activity, structure–activity relationship of series of 2‐(trifluoromethyl)benzo[b][1,8]naphthyridin‐4(1H)‐ones

  2018cites this paper
• Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents.

  2018cites this paper
• Slow pace of antileishmanial drug development

  2018cites this paper
• Studies Aimed at the Synthesis of Anti-Infective Agents

  2018cites this paper
• Leishmania donovani PP2C: Kinetics, structural attributes and in vitro immune response.

  2018cites this paper
• Prevalence of Cutaneous Leishmaniasis among HIV and Non-HIV Patients attending some Selected Hospitals in Jos Plateau State

  2018influential citation
• Chemotherapy and Experimental Models of Visceral Leishmaniasis

  2018cites this paper
• Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview

  2018cites this paper
• Crossing Biological Barriers for Leishmaniasis Therapy: From Nanomedicinal Targeting Perspective

  2018cites this paper
• Current Status of Existing and Emerging Chemotherapy and Drug Resistance Mechanisms in Leishmania

  2017cites this paper
• Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability

  2017cites this paper
• Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites

  2017cites this paper
• Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.

  2017cites this paper
• Cloning, characterization and subcellular localization of Nuclear LIM interactor interacting factor gene from Leishmania donovani.

  2017cites this paper
• Leishmania donovani resistant to Ambisome or Miltefosine exacerbates CD58 expression on NK cells and promotes trans‐membrane migration in association with CD2

  2017cites this paper
• Chapter 19 Alkylphospholipids and Leishmaniasis

  2017cites this paper
• In silico molecular docking studies of new potential 4-phthalazinyl-hydrazones on selected Trypanosoma cruzi and Leishmania enzyme targets.

  2017cites this paper
• Zinc depletion promotes apoptosis-like death in drug-sensitive and antimony-resistance Leishmania donovani

  2017cites this paper
• Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against Leishmania braziliensis.

  2017cites this paper
• An insight into tetrahydro-β-carboline-tetrazole hybrids: synthesis and bioevaluation as potent antileishmanial agents.

  2017cites this paper
• A RAPID, SENSITIVE AND VALIDATED ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY AND TANDEM MASS SPECTROMETRY METHOD FOR DETERMINATION OF PAROMOMYCIN IN MICE PLASMA: APPLICATION TO PHARMACOKINETIC STUDY

  2017cites this paper
• Drug resistance and treatment failure in leishmaniasis: A 21st century challenge

  2017cites this paper
• Chapter 6 – Antibiotic Resistance: Can Nanoparticles Tackle the Problem?

  2016cites this paper
• Caractérisation des mécanismes de réarrangements géniques chez le parasite Leishmania résistant aux drogues

  2016cites this paper
• Disclosing the essentiality of ribose-5-phosphate isomerase B in Trypanosomatids

  2016cites this paper
• Functional characterization of Leishmania infantum asparagine synthetase A and ribose 5-phosphate Isomerase B as potential drug targets

  2016influential citation
• Kala Azar in South Asia

  2016cites this paper
• Hepatic stellate cells regulate liver immunity to visceral leishmaniasis through P110δ‐dependent induction and expansion of regulatory T cells in mice

  2016cites this paper
• Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis

  2016cites this paper
• Regulation of Immunity to Visceral Leishmaniasis by Regulatory T cells (Tregs) and Hepatic Stellate Cells (HSCs)

  2016cites this paper
• The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis

  2016cites this paper
• Up-regulation of cytosolic tryparedoxin in Amp B resistant isolates of Leishmania donovani and its interaction with cytosolic tryparedoxin peroxidase.

  2016cites this paper
• Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field

  2016cites this paper
• The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases

  2016cites this paper